NJ State Employees Deferred Compensation Plan’s Viking Therapeutics VKTX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-79,320	Closed	-$2.08M	–	398
2025 Q3	$2.08M	Buy	79,320 +31,320	+65%	+$934K	0.23%	97
2025 Q2	$1.27M	Hold	48,000	–	–	0.15%	148
2025 Q1	$1.16M	Buy	48,000 +10,000	+26%	+$316K	0.15%	156
2024 Q4	$1.53M	Hold	38,000	–	–	0.19%	122
2024 Q3	$2.41M	Hold	38,000	–	–	0.29%	81
2024 Q2	$2.01M	Buy	38,000 +29,300	+337%	+$1.92M	0.25%	86
2024 Q1	$713K	Buy	+8,700	New	+$387K	0.09%	227

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's VKTX Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 79,320 shares — an estimated $2.08M sold.

NJ State Employees Deferred Compensation Plan first reported a position in VKTX in Q1 2024 and held it in 7 quarters. The position peaked at $2.41M in Q3 2024. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 79,320 Viking Therapeutics shares in Q4 2025, an estimated $2.08M.
NJ State Employees Deferred Compensation Plan first reported a position in Viking Therapeutics in Q1 2024 and held it in 7 quarters.
NJ State Employees Deferred Compensation Plan's Viking Therapeutics position peaked at $2.41M in Q3 2024.
426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.